[go: up one dir, main page]

MX2019004804A - Tratamiento para el prurigo nodula. - Google Patents

Tratamiento para el prurigo nodula.

Info

Publication number
MX2019004804A
MX2019004804A MX2019004804A MX2019004804A MX2019004804A MX 2019004804 A MX2019004804 A MX 2019004804A MX 2019004804 A MX2019004804 A MX 2019004804A MX 2019004804 A MX2019004804 A MX 2019004804A MX 2019004804 A MX2019004804 A MX 2019004804A
Authority
MX
Mexico
Prior art keywords
treatment
prurigo nodularis
nodularis
prurigo
patient
Prior art date
Application number
MX2019004804A
Other languages
English (en)
Inventor
Sciascia Thomas
Good Jennifer
Hawi Amale
Original Assignee
Trevi Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trevi Therapeutics Inc filed Critical Trevi Therapeutics Inc
Publication of MX2019004804A publication Critical patent/MX2019004804A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a métodos para tratar el prúrigo nodular con composiciones antipruríticas, en donde el método proporciona un efecto terapéutico en un paciente.
MX2019004804A 2016-10-25 2017-10-25 Tratamiento para el prurigo nodula. MX2019004804A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662412578P 2016-10-25 2016-10-25
PCT/US2017/058294 WO2018081273A1 (en) 2016-10-25 2017-10-25 Treatment of prurigo nodularis

Publications (1)

Publication Number Publication Date
MX2019004804A true MX2019004804A (es) 2019-08-22

Family

ID=62025443

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019004804A MX2019004804A (es) 2016-10-25 2017-10-25 Tratamiento para el prurigo nodula.

Country Status (11)

Country Link
US (3) US20180125840A1 (es)
EP (1) EP3532061A4 (es)
JP (2) JP2019532112A (es)
KR (1) KR102696347B1 (es)
CN (1) CN109862895A (es)
AU (1) AU2017350852A1 (es)
BR (1) BR112019008241A2 (es)
CA (1) CA3038544A1 (es)
MX (1) MX2019004804A (es)
NZ (1) NZ751972A (es)
WO (1) WO2018081273A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020014342A1 (en) * 2018-07-11 2020-01-16 Trevi Therapeutics, Inc. Treatment of the pruritic symptoms of liver disease
CN118512452A (zh) 2018-07-23 2024-08-20 特雷维治疗股份有限公司 慢性咳嗽、呼吸急促和呼吸困难的治疗
EP4087569A4 (en) * 2020-01-10 2024-01-24 Trevi Therapeutics, Inc. METHODS OF ADMINISTRATION OF NALBUPHINE
WO2023150579A2 (en) * 2022-02-01 2023-08-10 HUMANWELL PHARMACEUTICAL US, Inc. Pharmaceutical formulations containing nalbuphine

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005537298A (ja) * 2002-08-02 2005-12-08 ペンウェスト ファーマシューティカルズ カンパニー メトホルミンの徐放性製剤
JP2005162736A (ja) * 2003-11-10 2005-06-23 Astellas Pharma Inc 徐放性医薬組成物
BRPI0417123A (pt) * 2003-12-12 2007-08-21 Penwest Pharmaceutical Co formulação de torsemide de liberação prolongada
DK2402005T3 (da) * 2005-08-24 2021-03-15 Endo Pharmaceuticals Inc Formuleringer med langvarig frigivelse af nalbuphin
EP2240110A4 (en) * 2008-01-29 2015-07-01 Superdimension Ltd TARGET IDENTIFICATION INSTRUMENT FOR LOCALIZATION IN THE BODY
US8987289B2 (en) * 2012-12-14 2015-03-24 Trevi Therapeutics, Inc. Methods for treating pruritus
KR20220044385A (ko) * 2012-12-14 2022-04-07 트레비 테라퓨틱스, 인코포레이티드 소양증을 치료하는 방법
CN106535897A (zh) * 2014-06-13 2017-03-22 特雷维治疗股份有限公司 用于治疗瘙痒的方法
WO2017120468A1 (en) * 2016-01-06 2017-07-13 Trevi Therapeutics, Inc. Therapeutic use of nalbuphine without aquaretic effects
CN105560202B (zh) * 2016-03-11 2019-05-24 广州玻思韬控释药业有限公司 一种盐酸纳布啡凝胶骨架缓释片的制备方法及应用

Also Published As

Publication number Publication date
KR20190073385A (ko) 2019-06-26
US20220347171A1 (en) 2022-11-03
KR102696347B1 (ko) 2024-08-19
JP2022191405A (ja) 2022-12-27
EP3532061A4 (en) 2020-07-08
WO2018081273A1 (en) 2018-05-03
JP2019532112A (ja) 2019-11-07
NZ751972A (en) 2022-12-23
EP3532061A1 (en) 2019-09-04
CA3038544A1 (en) 2018-05-03
BR112019008241A2 (pt) 2019-07-16
US20230338367A1 (en) 2023-10-26
CN109862895A (zh) 2019-06-07
US20180125840A1 (en) 2018-05-10
AU2017350852A1 (en) 2019-04-11

Similar Documents

Publication Publication Date Title
MX2017010150A (es) Bacterias probioticas recombinantes.
MY190034A (en) Method of treating cancer associated with a ras mutation
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
MX2018003936A (es) Anticuerpos anti proteina de muerte celular programada 1 (pd-1) y composiciones.
MA39906A (fr) Polythérapies pour le traitement du cancer
ZA202005388B (en) Methods of treating ulcerative colitis
EA201791208A1 (ru) Антитела к cd38 для лечения острого миелолейкоза
EA201891340A1 (ru) Лечение рака с использованием 2-дезокси-2-фтор-l-фукозы в комбинации с ингибитором контрольных точек
MY194341A (en) Method of treating a brain tumor
MX377593B (es) Composiciones para usar en el tratamiento de cáncer renal.
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
EA201790442A1 (ru) Трициклические азотсодержащие соединения для лечения инфекции, вызываемой neisseria gonorrhoeae
MX2016015378A (es) Uso de eribulina en el tratamiento de cancer.
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
MX2016014559A (es) Compuestos para el tratamiento de cancer.
MX2017006026A (es) Apilimod para uso en el tratamiento de cancer colorrectal.
PH12016502150A1 (en) Method for treating renal cell carcimona
MX2017000306A (es) Metodos para tratar hipotension.
TW201613587A (en) Medical treatments based on anamorelin
MX2019004804A (es) Tratamiento para el prurigo nodula.
MX382044B (es) Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estrés.
MX2020009966A (es) Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina.
PH12017501872A1 (en) Methods of treating diseases
MY203831A (en) Treatment and diagnosis of inflammatory disorders
MX382608B (es) Tratamiento del prurito urémico.